GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Recursion Pharmaceuticals Inc (NAS:RXRX) » Definitions » Cash per Share

Recursion Pharmaceuticals (Recursion Pharmaceuticals) Cash per Share : $1.68 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Recursion Pharmaceuticals Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Recursion Pharmaceuticals's Cash per Share for the quarter that ended in Dec. 2023 was $1.68.

Recursion Pharmaceuticals Cash per Share Historical Data

The historical data trend for Recursion Pharmaceuticals's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Recursion Pharmaceuticals Cash per Share Chart

Recursion Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Cash per Share
0.62 1.68 3.03 2.88 1.68

Recursion Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.88 2.46 2.00 1.80 1.68

Recursion Pharmaceuticals Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Recursion Pharmaceuticals's Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=391.565/233.81
=1.67

Recursion Pharmaceuticals's Cash per Share for the quarter that ended in Dec. 2023 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=391.565/233.81
=1.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Recursion Pharmaceuticals  (NAS:RXRX) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Recursion Pharmaceuticals Cash per Share Related Terms

Thank you for viewing the detailed overview of Recursion Pharmaceuticals's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Recursion Pharmaceuticals (Recursion Pharmaceuticals) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Recursion Pharmaceuticals Inc (NAS:RXRX) » Definitions » Cash per Share
Comparable Companies
MNKD BCRX MIRM EQRX KNSA XNCR IRON VIR CLDX DAWN OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
41 S Rio Grande Street, Salt Lake City,, UT, USA, 84101
Website
https://www.recursion.com
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
Executives
Michael Secora officer: Chief Financial Officer C/O RECURSION PHARMACEUTICALS, 41 S. RIO GRANDE STREET, SALT LAKE CITY UT 84101
Shafique Virani officer: Chief Corp. Dev. Officer C/O RECURSION PHARMACEUTICALS, 41 S. RIO GRANDE STREET, SALT LAKE CITY UT 84101
Dean Y Li director 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Blake Borgeson director C/O RECURSION PHARMACEUTICALS, 41 S. RIO GRANDE STREET, SALT LAKE CITY UT 84101
Christopher Gibson director, 10 percent owner, officer: Chief Executive Officer C/O RECURSION PHARMACEUTICALS, 41 S. RIO GRANDE STREET, SALT LAKE CITY UT 84101
Tina Marriott Larson officer: President and COO C/O RECURSION PHARMACEUTICALS, 41 S. RIO GRANDE STREET, SALT LAKE CITY UT 84101
Zavain Dar director C/O LUX CAPITAL MANAGEMENT, LLC, 1600 EL CAMINO REAL - SUITE 290, MENLO PARK CA 94025
Terry-ann Burrell director C/O BEAM THERAPEUTICS INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
David J Mauro officer: Chief Medical Officer 36 TERRELL DRIVE, WASHINGTON CROSS PA 18977
Mubadala Investment Co Pjsc 10 percent owner P.O. BOX 45005, ABU DHABI C0 00000
Peter Hebert other: Former 10% Owner C/O LUX VENTURES, 295 MADISON AVE, 24TH FLOOR, NEW YORK NY 10017
Lux Ventures Iv, L.p. other: Former 10% Owner 295 MADISON AVENUE, 24TH FLOOR, NEW YORK NY 10017
Lux Venture Partners Iv, Llc other: Former 10% Owner 920 BROADWAY, 11TH FLOOR, NEW YORK NY 10010
Lux Co-invest Partners, Llc other: Former 10% Owner C/O LUX CAPITAL, 920 BROADWAY, 11TH FLOOR, NEW YORK NY 10010
Lux Co-invest Opportunities, L.p. other: Former 10% Owner C/O LUX CAPITAL MANAGEMENT, 920 BROADWAY, 11TH FLOOR, NEW YORK NY 10010